Biocon Biologics and Viatris’s Semglee preferred on Express Scripts’ largest formulary in US Read more
Inter-changeable designation for Semglee in the US is a milestone achievement for Biocon Biologics Read more
Biocon Biologics and Viatris receive US FDA approval for maiden interchangeable biosimilar Semglee Read more
Biocon and Voluntis deal to transform insulin biosimilars personalised care through digital therapeutics: GlobalData Read more
Biocon’s partner Mylan receives favourable ruling from US PTAB on Sanofi’s four device patents for Lantus SoloSTAR Read more